GTS Securities’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

GTS Securities’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-25,144	Closed	-$252K	–	4604
2023 Q4	$252K	Buy	+25,144	New	+$114K	﹤0.01%	3365

GTS Securities's GRCL Position: Q1 2024 in Review

GTS Securities sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 25,144 shares — an estimated $252K sold.

GTS Securities first reported a position in GRCL in Q4 2023 and held it in 1 quarter. The position peaked at $252K in Q4 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

GTS Securities reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
GTS Securities sold 25,144 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $252K.
GTS Securities first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q4 2023 and held it in 1 quarter.
GTS Securities's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $252K in Q4 2023.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on GTS Securities's 13F filing for Q1 2024, filed 15 May 2024.